Cullinan Therapeutics

Q2 FY2026 EarningsQ2 FY26 results for CGEM.US showed a narrower-than-expected loss, with GAAP EPS of -$0.81 beating the -$0.80 consensus by $0.01. Operating expenses were significantly lower than anticipated, particularly in R&D, which fell 27.2% YoY to $44.4M. With a robust cash balance of $356M, the company extended its operational runway into 2029, while key clinical catalysts for CLN-978 and velinotamig remain on track for Q3 and Q4 2026.